Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 9:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 10,845 matching trials from the live ClinicalTrials.gov search.
Filters: Columbus, Ohio Clear all
Terminated Not applicable Interventional Results available

Arthrex Eclipse™ Shoulder Prosthesis

NCT01790113
View directory record Official record
Conditions
Osteoarthritis
Interventions
Univers™, Eclipse™ Total Shoulder Replacement
Device
Lead sponsor
Arthrex, Inc.
Industry
Eligibility
21 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
16
States / cities
Sun City, Arizona • Redwood City, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 31, 2026, 9:02 PM EDT
Completed Not applicable Interventional

Cognitive-Behavioral Intervention for Worry, Uncertainty, and Insomnia for Cancer Survivors

NCT01929720
View directory record Official record
Conditions
Anxiety Disorder, Worry, Uncertainty, Sleep Disorders, Insomnia, Fatigue, Pain, Depression, Cognitive-behavioral Therapy, Psychological Intervention, Esophageal Cancer, Pancreatic Cancer, Leukemia, Lung Cancer, Multiple Myeloma, Ovarian Neoplasm, Stage III or IV Cervical or Uterine Cancer, Stage IIIB, IIIC, or IV Breast Cancer, Glioblastoma Multiforme, Relapsed Lymphoma, Stage III or IV Colorectal Cancer, Stage IIIC or IV Melanoma
Interventions
Cognitive-behavioral therapy for worry, uncertainty & insomnia
Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Oct 31, 2026, 9:02 PM EDT
Completed Phase 3 Interventional

Study of the Long-Term Safety of Pramlintide in Subjects With Type 1 Diabetes Mellitus

NCT00107107
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
pramlintide acetate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
25
States / cities
Tempe, Arizona • Concord, California • Fresno, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2015 · Synced Oct 31, 2026, 9:02 PM EDT
Active, not recruiting Not applicable Interventional

Survivorship of Attune Primary Total Knee Prosthesis

NCT01754363
View directory record Official record
Conditions
Noninflammatory Degenerative Joint Disease
Interventions
Attune Primary Total Knee Replacement
Device
Lead sponsor
DePuy International
Industry
Eligibility
22 Years to 75 Years
Enrollment
1,542 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2030
U.S. locations
9
States / cities
Scottsdale, Arizona • Orange, California • DeLand, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 31, 2026, 9:02 PM EDT
Completed Phase 3 Interventional Results available

LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

NCT03103087
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Uterine Fibroid
Interventions
Relugolix, Estradiol/norethindrone acetate, Relugolix placebo, Estradiol/norethindrone acetate placebo
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
89
States / cities
Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Oct 31, 2026, 9:02 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

NCT05601882
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab, Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years to 64 Years
Enrollment
920 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
58
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • North Little Rock, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2025 · Synced Oct 31, 2026, 9:02 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)

NCT02073279
View directory record Official record
Conditions
Neuromyelitis Optica (NMO), NMO Spectrum Disorder (NMOSD)
Interventions
Satralizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 74 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
20
States / cities
Aurora, Colorado • Miami, Florida • Vero Beach, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Oct 31, 2026, 9:02 PM EDT
Completed Phase 1Phase 2 Interventional

IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer

NCT04434482
View directory record Official record
Conditions
Advanced Solid Tumours, Small Cell Lung Cancer
Interventions
IMP4297(senaparib)
Drug
Lead sponsor
Impact Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
Evergreen Park, Illinois • Canton, Ohio • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 31, 2026, 9:02 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Study of AL102 in Patients With Progressing Desmoid Tumors

NCT04871282
View directory record Official record
Conditions
Desmoid, Desmoid Tumor
Interventions
AL102, Placebo
Drug · Other
Lead sponsor
Immunome, Inc.
Industry
Eligibility
12 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
23
States / cities
Pheonix, Arizona • Duarte, California • Santa Monica, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 31, 2026, 9:02 PM EDT
Terminated Phase 3 Interventional

Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum

NCT05964413
View directory record Official record
Conditions
Pyoderma Gangrenosum
Interventions
vilobelimab, Placebo
Drug
Lead sponsor
InflaRx GmbH
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
12
States / cities
Hialeah, Florida • Miami, Florida • Orlando, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 31, 2026, 9:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

All in Dads! Healthy Marriage and Responsible Fatherhood Program Evaluation

NCT05194020
View directory record Official record
Conditions
Fathers
Interventions
Primary Services
Other
Lead sponsor
Midwest Evaluation & Research
Other
Eligibility
18 Years and older · Male only
Enrollment
731 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 31, 2026, 9:02 PM EDT
Terminated Phase 3 Interventional

Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma

NCT01168791
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
Palifosfamide-Tris, doxorubicin, Placebo
Drug
Lead sponsor
Alaunos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
73
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 31, 2026, 9:02 PM EDT
Completed No phase listed Observational

Transplant-Related Mortality in Patients Undergoing a Peripheral Blood Stem Cell Transplantation or an Umbilical Cord Blood Transplantation

NCT02188290
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
Interventions
Not listed
Lead sponsor
Kiadis Pharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 6, 2015 · Synced Oct 31, 2026, 9:02 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)

NCT05540860
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Sevasemten Dose 1, Sevasemten Dose 2, Sevasemten Dose 3, Sevasemten Dose 4, Sevasemten Dose 5, Placebo
Drug
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Eligibility
4 Years to 9 Years · Male only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
14
States / cities
Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 31, 2026, 9:02 PM EDT
Terminated Phase 3 Interventional Results available

An Efficacy and Safety Study of Ravulizumab in ALS Participants

NCT04248465
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, ALS
Interventions
Placebo, Ravulizumab
Drug · Biological
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
34
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Loma Linda, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Oct 31, 2026, 9:02 PM EDT
Recruiting Phase 3 Interventional

A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase Administration Via Subcutaneous and Intravenous Routes Both With Methotrexate in Participants With Uncontrolled Gout

NCT07388498
View directory record Official record
Conditions
Uncontrolled Gout
Interventions
Pegloticase, Methotrexate
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
74
States / cities
Birmingham, Alabama • Anchorage, Alaska • Searcy, Arkansas + 58 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 31, 2026, 9:02 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)

NCT03157128
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
Interventions
LOXO-292
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
857 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
41
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 31, 2026, 9:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of Wear Experience With One Week Reusable Contact Lenses in Habitual Two Week Reusable Lens Wearers

NCT06382064
View directory record Official record
Conditions
Myopia
Interventions
Biweekly replacement contact lenses, One week replacement contact lenses
Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 31, 2026, 9:02 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Examining Heavy Metal Exposure and Respiratory Health in Young Adult Electronic Cigarette Users

NCT07215065
View directory record Official record
Conditions
Heavy Metal Exposure From Vaping
Interventions
Non-Interventional Study
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 29 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 31, 2026, 9:02 PM EDT
Completed Phase 3 Interventional Results available

An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients

NCT02003144
View directory record Official record
Conditions
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Interventions
eculizumab
Biological
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
19
States / cities
Scottsdale, Arizona • Oceanside, California • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Oct 31, 2026, 9:02 PM EDT
Completed Phase 3 Interventional Results available

Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

NCT00005044
View directory record Official record
Conditions
Prostate Cancer
Interventions
Casodex, Eulexin, LHRH agonist, radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years · Male only
Enrollment
1,579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2022
U.S. locations
241
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 181 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2022 · Synced Oct 31, 2026, 9:02 PM EDT
Recruiting Not applicable Interventional

Inspiratory Muscle Training for Breast Cancer Patients on Chemotherapy

NCT07386444
View directory record Official record
Conditions
Early Stage Breast Carcinoma, Dyspnea
Interventions
Inspiratory muscle training
Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 31, 2026, 9:02 PM EDT
Completed No phase listed Observational

Rest Before Physical Therapy in Adolescents With Active Spondylolysis and Spondylolisthesis

NCT02332200
View directory record Official record
Conditions
Spondylolysis, Spondylolisthesis, Low Back Pain
Interventions
Physical Therapy
Other
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
Not listed
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
4
States / cities
Columbus, Ohio • Dublin, Ohio • Westerville, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Oct 31, 2026, 9:02 PM EDT
Recruiting Phase 3 Interventional

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

NCT06757634
View directory record Official record
Conditions
Breast Cancer
Interventions
Arm A: Gedatolisib + Palbociclib + Fulvestrant, Arm B: Ribociclib + Fulvestrant, Arm C: Gedatolisib + Palbociclib + Letrozole, Arm D: Ribociclib + Letrozole
Drug
Lead sponsor
Celcuity Inc
Industry
Eligibility
18 Years and older
Enrollment
1,180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
30
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • Duarte, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 31, 2026, 9:02 PM EDT